PriceTargets.com logo

Castle Biosciences - CSTL Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $52.00
  • Forecasted Upside: 134.66%
  • Number of Analysts: 6
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 6 Buy Ratings
  • 0 Strong Buy Ratings
$22.16 As of 03/23/2023 01:00 AM ET
▲ +0.6 (2.78%)

This chart shows the closing price for CSTL by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Castle Biosciences Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CSTL and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CSTL

Analyst Price Target is $52.00
▲ +134.66% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Castle Biosciences in the last 3 months. The average price target is $52.00, with a high forecast of $80.00 and a low forecast of $38.00. The average price target represents a 134.66% upside from the last price of $22.16.

This chart shows the closing price for CSTL for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 6 investment analysts is to buy stock in Castle Biosciences. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/29/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/28/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/28/2022
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/26/2022
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/24/2022
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/23/2022
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/21/2023
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/23/2023

Latest Recommendations

  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/2/2023StephensReiterated RatingOverweight$41.00Low
3/1/2023Lake Street CapitalLower Target$63.00 ➝ $41.00Low
3/1/2023Robert W. BairdLower TargetOutperform$42.00 ➝ $38.00Low
1/4/2023ScotiabankInitiated CoverageSector Outperform$54.00Low
11/3/2022Robert W. BairdLower TargetOutperform$48.00 ➝ $41.00Low
8/15/2022BTIG ResearchBoost Target$47.00N/A
8/9/2022Robert W. BairdBoost TargetOutperform$44.00 ➝ $48.00Low
8/9/2022SVB LeerinkBoost TargetMarket Outperform$45.00 ➝ $50.00Low
5/10/2022Canaccord Genuity GroupLower Target$80.00 ➝ $65.00High
5/10/2022Robert W. BairdLower Target$50.00 ➝ $44.00High
4/5/2022Canaccord Genuity GroupLower TargetBuy$94.00 ➝ $80.00High
4/5/2022Canaccord Genuity GroupLower TargetBuy ➝ Buy$94.00 ➝ $80.00High
3/1/2022Lake Street CapitalLower Target$94.00 ➝ $63.00Medium
3/1/2022Robert W. BairdLower Target$82.00 ➝ $60.00High
1/7/2022StephensInitiated CoverageOverweight$59.00Medium
11/9/2021SVB LeerinkLower TargetOutperform$85.00 ➝ $75.00High
11/9/2021Robert W. BairdBoost TargetOutperform$78.00 ➝ $82.00High
8/10/2021Robert W. BairdBoost TargetOutperform$73.00 ➝ $78.00High
7/14/2021SVB LeerinkBoost TargetOutperform$80.00 ➝ $85.00High
5/13/2021Robert W. BairdReiterated RatingBuy$73.00High
4/30/2021Lake Street CapitalInitiated CoverageBuy$94.00Low
3/9/2021Robert W. BairdLower TargetOutperform$87.00 ➝ $82.00Low
2/3/2021KeyCorpBoost TargetOverweight$70.00 ➝ $90.00Low
1/15/2021SVB LeerinkBoost TargetOutperform$70.00 ➝ $80.00High
12/17/2020BTIG ResearchBoost TargetBuy$60.00 ➝ $80.00High
12/11/2020SVB LeerinkBoost TargetOutperform$57.00 ➝ $70.00High
11/9/2020KeyCorpInitiated CoverageOverweight$70.00High
9/25/2020SVB LeerinkBoost TargetOutperform$50.00 ➝ $57.00Low
8/11/2020SVB LeerinkBoost TargetOutperform$45.00 ➝ $50.00High
5/12/2020SVB LeerinkBoost TargetOutperform$40.00 ➝ $45.00High
3/27/2020Robert W. BairdLower TargetOutperform$38.00 ➝ $35.00Medium
3/11/2020BTIG ResearchBoost Target$32.00 ➝ $41.00High
3/11/2020SVB LeerinkBoost TargetOutperform$35.00 ➝ $40.00High
3/11/2020Robert W. BairdBoost TargetOutperform$37.00 ➝ $38.00High
9/4/2019SVB LeerinkSet TargetBuy$33.00Low
9/4/2019Robert W. BairdBoost TargetOutperform$27.00 ➝ $31.00High
9/4/2019BTIG ResearchBoost TargetBuy$32.00High
8/19/2019BTIG ResearchInitiated CoverageBuy$25.00High
8/19/2019SVB LeerinkInitiated CoverageOutperform$28.00High
8/19/2019Robert W. BairdInitiated CoverageOutperform$27.00High
(Data available from 3/23/2018 forward)

News Sentiment Rating

0.40 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 4 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/25/2022
  • 6 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/24/2022
  • 3 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
10/24/2022
  • 7 very positive mentions
  • 8 positive mentions
  • 2 negative mentions
  • 2 very negative mentions
Mentions as of
11/23/2022
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/23/2022
  • 5 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
1/22/2023
  • 10 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/21/2023
  • 3 very positive mentions
  • 10 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
3/23/2023

Current Sentiment

  • 3 very positive mentions
  • 10 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Castle Biosciences logo
Castle Biosciences, Inc. is a commercial-stage dermatological cancer company, which engages in the provision of genomic information for physicians and patients. The firm offers DecisionDx-Melanoma, a proprietary multi-gene expression profile (GEP) test that predicts the risk of metastasis and recurrence for patients diagnosed with invasive cutaneous melanoma. It also markets DecisionDx-UM, Decision Dx DiffDx-Melanoma, DecisonDx-CMSeq, DecisionDx-SCC, DecsionDx-UMSeq, and DecisonDX-PRAME. The company was founded by Derek J. Maetzold in September 2007 and is headquartered in Friendswood, TX.
Read More

Today's Range

Now: $22.16
Low: $21.61
High: $22.64

50 Day Range

MA: $24.84
Low: $19.47
High: $28.49

52 Week Range

Now: $22.16
Low: $15.58
High: $47.27

Volume

135,290 shs

Average Volume

154,253 shs

Market Capitalization

$589.01 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.05

Frequently Asked Questions

What sell-side analysts currently cover shares of Castle Biosciences?

The following Wall Street analysts have issued reports on Castle Biosciences in the last twelve months: BTIG Research, Canaccord Genuity Group Inc., Lake Street Capital, Robert W. Baird, Scotiabank, Stephens, and SVB Leerink LLC.
View the latest analyst ratings for CSTL.

What is the current price target for Castle Biosciences?

8 Wall Street analysts have set twelve-month price targets for Castle Biosciences in the last year. Their average twelve-month price target is $52.00, suggesting a possible upside of 134.7%. Canaccord Genuity Group Inc. has the highest price target set, predicting CSTL will reach $80.00 in the next twelve months. Robert W. Baird has the lowest price target set, forecasting a price of $38.00 for Castle Biosciences in the next year.
View the latest price targets for CSTL.

What is the current consensus analyst rating for Castle Biosciences?

Castle Biosciences currently has 6 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CSTL will outperform the market and that investors should add to their positions of Castle Biosciences.
View the latest ratings for CSTL.

What other companies compete with Castle Biosciences?

Other companies that are similar to Castle Biosciences include Progenity, CareDx, Invitae, Fulgent Genetics and Celcuity. Learn More about companies similar to Castle Biosciences.

How do I contact Castle Biosciences' investor relations team?

Castle Biosciences' physical mailing address is 820 S FRIENDSWOOD DRIVE SUITE 201, FRIENDSWOOD TX, 77546. The company's listed phone number is (866) 788-9007 and its investor relations email address is [email protected] The official website for Castle Biosciences is castlebiosciences.com. Learn More about contacing Castle Biosciences investor relations.